Abstract
Osteophytes are a prominent feature of osteoarthritis (OA) pathology. RNA-seq of osteophytes revealed patterns corresponding to active ECM re-modulation and participation of mast cells. The cells recruitment and their activity status were confirmed by anti-TPSAB1 and anti-FC epsilon RI antibodies in immunohistochemistry. Besides subchondral bone, which is a logical yet unproven route for the cells deployment into osteophytes, the authors propose that OA synovial fluid (SF) is necessary and sufficient for maturation of mast cell precursors (MCPs) in this channel. The authors present evidences to support their claim in the form of IHC, proteomics analysis of SF samples and in vitro cell differentiation assay, wherein human monocytes (ThP1) and hematopoietic stem cells (HSCs) showed differentiation in HLA-DR+/CD206+ and FCERI+ phenotype respectively after 9 days of SF treatment. These observations expound osteophytes and resident mast cells as yet unexplained functional epicentre in OA pathology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
INNO-INDIGO, funding scheme for Indo-European cooperation projects [funding /project ID - OAIBGE/2015(G)]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All methods performed in this research study abide by the Declaration 363 of Helsinki and the study protocols were approved by the Institutional Ethics Committee of University of Tartu (227/T-14 and 76785)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email – Priya Kulkarni – pgkulkarni2610{at}gmail.com; Abhay Harsulkar – aharsulkar{at}yahoo.com; Anne-Grete Märtson – annegretem{at}icloud.com, a.martson{at}liverpool.ac.uk; Siim Suutre – siim.suutre{at}ut.ee; Aare Märtson – Aare.Martson{at}kliinikum.ee
Data Availability
All data produced in the present study are available upon reasonable request to the authors